130 related articles for article (PubMed ID: 15883125)
1. False-positive findings on [18F]FDG-PET caused by non-neoplastic cellular elements after neoadjuvant chemoradiotherapy for non-small cell lung cancer.
Ohtsuka T; Nomori H; Watanabe K; Naruke T; Orikasa H; Yamazaki K; Suemasu K; Uno K
Jpn J Clin Oncol; 2005 May; 35(5):271-3. PubMed ID: 15883125
[TBL] [Abstract][Full Text] [Related]
2. Imaging cellular proliferation during chemo-radiotherapy: a pilot study of serial 18F-FLT positron emission tomography/computed tomography imaging for non-small-cell lung cancer.
Everitt S; Hicks RJ; Ball D; Kron T; Schneider-Kolsky M; Walter T; Binns D; Mac Manus M
Int J Radiat Oncol Biol Phys; 2009 Nov; 75(4):1098-104. PubMed ID: 19386444
[TBL] [Abstract][Full Text] [Related]
3. Prospective comparison of 18F-FDG PET with conventional imaging modalities (MRI, CT, and 67Ga scintigraphy) in assessment of combined intraarterial chemotherapy and radiotherapy for head and neck carcinoma.
Kitagawa Y; Nishizawa S; Sano K; Ogasawara T; Nakamura M; Sadato N; Yoshida M; Yonekura Y
J Nucl Med; 2003 Feb; 44(2):198-206. PubMed ID: 12571209
[TBL] [Abstract][Full Text] [Related]
4. Areas of high 18F-FDG uptake on preradiotherapy PET/CT identify preferential sites of local relapse after chemoradiotherapy for non-small cell lung cancer.
Calais J; Thureau S; Dubray B; Modzelewski R; Thiberville L; Gardin I; Vera P
J Nucl Med; 2015 Feb; 56(2):196-203. PubMed ID: 25572091
[TBL] [Abstract][Full Text] [Related]
5. Correlation of PET/CT findings and histopathology after neoadjuvant therapy in non-small cell lung cancer.
Poettgen C; Theegarten D; Eberhardt W; Levegruen S; Gauler T; Krbek T; Stamatis G; Teschler H; Kuehl H; Bockisch A; Stuschke M
Oncology; 2007; 73(5-6):316-23. PubMed ID: 18497503
[TBL] [Abstract][Full Text] [Related]
6. Adaptive Neoadjuvant Chemotherapy Guided by (18)F-FDG PET in Resectable Non-Small Cell Lung Cancers: The NEOSCAN Trial.
Chaft JE; Dunphy M; Naidoo J; Travis WD; Hellmann M; Woo K; Downey R; Rusch V; Ginsberg MS; Azzoli CG; Kris MG
J Thorac Oncol; 2016 Apr; 11(4):537-44. PubMed ID: 26724474
[TBL] [Abstract][Full Text] [Related]
7. Impact of computed tomography and 18F-deoxyglucose coincidence detection emission tomography image fusion for optimization of conformal radiotherapy in non-small-cell lung cancer.
Deniaud-Alexandre E; Touboul E; Lerouge D; Grahek D; Foulquier JN; Petegnief Y; Grès B; El Balaa H; Keraudy K; Kerrou K; Montravers F; Milleron B; Lebeau B; Talbot JN
Int J Radiat Oncol Biol Phys; 2005 Dec; 63(5):1432-41. PubMed ID: 16125870
[TBL] [Abstract][Full Text] [Related]
8. FDG-PET imaging for lymph node staging and pathologic tumor response after neoadjuvant treatment of non-small cell lung cancer.
Ohtsuka T; Nomori H; Ebihara A; Watanabe K; Kaji M; Naruke T; Suemasu K; Uno K
Ann Thorac Cardiovasc Surg; 2006 Apr; 12(2):89-94. PubMed ID: 16702929
[TBL] [Abstract][Full Text] [Related]
9. When is it best to repeat a 2-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography scan on patients with non-small cell lung cancer who have received neoadjuvant chemoradiotherapy?
Cerfolio RJ; Bryant AS
Ann Thorac Surg; 2007 Oct; 84(4):1092-7. PubMed ID: 17888953
[TBL] [Abstract][Full Text] [Related]
10. Repeat FDG-PET after neoadjuvant therapy is a predictor of pathologic response in patients with non-small cell lung cancer.
Cerfolio RJ; Bryant AS; Winokur TS; Ohja B; Bartolucci AA
Ann Thorac Surg; 2004 Dec; 78(6):1903-9; discussion 1909. PubMed ID: 15560998
[TBL] [Abstract][Full Text] [Related]
11. Positron emission tomography scanning with 2-fluoro-2-deoxy-d-glucose as a predictor of response of neoadjuvant treatment for non-small cell carcinoma.
Cerfolio RJ; Ojha B; Mukherjee S; Pask AH; Bass CS; Katholi CR
J Thorac Cardiovasc Surg; 2003 Apr; 125(4):938-44. PubMed ID: 12698159
[TBL] [Abstract][Full Text] [Related]
12. Metabolic (FDG-PET) response after radical radiotherapy/chemoradiotherapy for non-small cell lung cancer correlates with patterns of failure.
Mac Manus MP; Hicks RJ; Matthews JP; Wirth A; Rischin D; Ball DL
Lung Cancer; 2005 Jul; 49(1):95-108. PubMed ID: 15949595
[TBL] [Abstract][Full Text] [Related]
13. Impact of FDG-PET on radiation therapy volume delineation in non-small-cell lung cancer.
Bradley J; Thorstad WL; Mutic S; Miller TR; Dehdashti F; Siegel BA; Bosch W; Bertrand RJ
Int J Radiat Oncol Biol Phys; 2004 May; 59(1):78-86. PubMed ID: 15093902
[TBL] [Abstract][Full Text] [Related]
14. [PET with (18)F-fluorodeoxyglucose for staging of non-small cell lung cancer].
Weber WA; Dietlein M; Hellwig D; Kirsch CM; Schicha H; Schwaiger M
Nuklearmedizin; 2003 Aug; 42(4):135-44. PubMed ID: 12937692
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of Glut1 in lymphoid follicles correlates with false-positive (18)F-FDG PET results in lung cancer staging.
Chung JH; Cho KJ; Lee SS; Baek HJ; Park JH; Cheon GJ; Choi CW; Lim SM
J Nucl Med; 2004 Jun; 45(6):999-1003. PubMed ID: 15181136
[TBL] [Abstract][Full Text] [Related]
16. Non-small cell lung cancer: prospective comparison of integrated FDG PET/CT and CT alone for preoperative staging.
Shim SS; Lee KS; Kim BT; Chung MJ; Lee EJ; Han J; Choi JY; Kwon OJ; Shim YM; Kim S
Radiology; 2005 Sep; 236(3):1011-9. PubMed ID: 16014441
[TBL] [Abstract][Full Text] [Related]
17. Differential (18)F-FDG and (18)F-FLT Uptake on Serial PET/CT Imaging Before and During Definitive Chemoradiation for Non-Small Cell Lung Cancer.
Everitt SJ; Ball DL; Hicks RJ; Callahan J; Plumridge N; Collins M; Herschtal A; Binns D; Kron T; Schneider M; MacManus M
J Nucl Med; 2014 Jul; 55(7):1069-74. PubMed ID: 24833494
[TBL] [Abstract][Full Text] [Related]
18. Effect of Platinum-Based Chemoradiotherapy on Cellular Proliferation in Bone Marrow and Spleen, Estimated by (18)F-FLT PET/CT in Patients with Locally Advanced Non-Small Cell Lung Cancer.
Leimgruber A; Möller A; Everitt SJ; Chabrot M; Ball DL; Solomon B; MacManus M; Hicks RJ
J Nucl Med; 2014 Jul; 55(7):1075-80. PubMed ID: 24868108
[TBL] [Abstract][Full Text] [Related]
19. Correlation of Glut-1 glucose transporter expression with.
Higashi K; Ueda Y; Sakurai A; Wang XM; Xu L; Murakami M; Seki H; Oguchi M; Taki S; Nambu Y; Tonami H; Katsuda S; Yamamoto I
Eur J Nucl Med; 2000 Dec; 27(12):1778-85. PubMed ID: 11189940
[TBL] [Abstract][Full Text] [Related]
20. Does whole-body 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography have an advantage over thoracic positron emission tomography for staging patients with lung cancer?
Aquino SL; Fischman AJ
Chest; 2004 Sep; 126(3):755-60. PubMed ID: 15364753
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
